<DOC>
	<DOC>NCT00932802</DOC>
	<brief_summary>The observation period for each patient covered an initial treatment period with AveloxÂ® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.</brief_summary>
	<brief_title>Greatest International Antiinfective Trial With Avelox</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchial Diseases</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin Exclusion criteria must be read in conjunction with the local product information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Non-Interventional</keyword>
	<keyword>Observational</keyword>
	<keyword>NIS</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>MXF</keyword>
	<keyword>Avelox</keyword>
	<keyword>AECB</keyword>
</DOC>